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Abstract 
Background 
Antibodies directed against human leucocyte antigens (HLA) can develop through 
pregnancy, blood transfusions or organ transplants. Anecdotal evidence suggests that virus-
specific antibodies may have the capacity to cross-react with HLA, a phenomenon called 
heterologous immunity, which is well described for T cell alloreactivity. 
Methods 
To determine whether antibody cross-reactivity between viral antigens and HLA is common, 
we tested  51 virus-specific human monoclonal antibodies (mAbs) specific for human 
immunodeficiency virus (HIV), varicella zoster virus (VZV), cytomegalovirus (CMV), and 
parvovirus, for reactivity against HLA class I and class II in single antigen bead assays. In 
addition, we tested the reactivity of 41 HLA-specific human mAbs against common viral 
antigens of CMV, VZV, HIV, Epstein-Barr virus, and BK polyomavirus. 
Results 
No cross-reactivity of any of the virus-specific mAbs with either HLA class I or class II 
molecules, as well as no cross-reactivity of any of the HLA-specific mAbs with any of the 
viral antigens was observed. 
Conclusions 
These findings indicate that the frequency of cross-reactivity on the antibody level between 
viral antigens and HLA, if present at all, is low. The emergence of HLA antibodies upon viral 
infection or vaccination is therefore probably due to bystander activation of dormant HLA-
specific memory B cells. 
  
Introduction 
It is well recognized that sensitization against human leucocyte antigens (HLA) can be 
caused by pregnancies, blood transfusions, and organ transplants. Sensitization leads to the 
formation of alloantibodies, but also to circulating alloreactive memory B cells and T cells. 
Counter-intuitively, relatively high frequencies of alloreactive memory T cells exist in 
individuals not having experienced any of the sensitizing events described above.1 This is 
explained by a phenomenon called heterologous immunity, in which memory T cells specific 
for viral peptides presented in self-HLA can respond to foreign HLA.2 This cross-reactivity is 
due to the structural similarity between the complex of viral peptide with self-HLA, and 
allogeneic HLA.3 Cross-reactivity appears to be a common feature of virus-specific T cells, 
with HLA reactivity described for T cells formed against Epstein-Barr virus (EBV),4,5 
cytomegalovirus (CMV),6,7 varicella zoster virus (VZV),6-8 Influenza A,6,7 and human 
immunodeficiency virus (HIV).9 Cross-reactivity between virus-specific T cells and 
allogeneic HLA appears to be rather common, since it was shown that 80% of virus specific 
T cell lines and 45% of virus-specific T cell cross-reacted to allogeneic HLA.6 Such cross-
reactivity works both ways, as allo-HLA stimulated T cells can lyse both EBV and CMV 
peptide-loaded autologous cells.10  
Whether similar cross-reactivity of virus-specific antibodies with foreign HLA exists remains 
elusive. Increased HLA antibody formation upon viral infection or vaccination has been 
described anecdotally,11-13 although this could be due to either heterologous immunity, 
bystander activation of dormant B cell clones, or a combination of the two.14 If viral 
infections would lead to de novo HLA antibody development, screening for HLA antibodies 
upon viral infections in patients awaiting an organ transplant may be required,11 although this 
notion is highly controversial.15,16 To determine whether cross-reactivity of antibodies 
between viral antigens and HLA is likely to exist, we tested 51 virus-specific human 
monoclonal antibodies  (mAbs) with specificity for HIV-1, VZV, CMV or parvovirus, 
against HLA class I and HLA class II molecules in single antigen bead (SAB) assays. In 
addition, we tested the reactivity of a panel of 41 HLA-specific human mAbs against various 
viral antigens. We hypothesized that a proportion of human virus-specific mAbs would react 
to HLA, and/or a proportion of human HLA-specific mAbs would react to viral antigens, in 
case heterologous immunity on the level of humoral immunity would be prevalent. 
 
Materials and methods 
Human monoclonal antibodies 
Virus-specific human mAbs were obtained from various sources and were specific for 
different viruses (table 1). The HIV-1-specific mAbs 37G12, 2F5, 4E10, 3D6, 5F3, 4B3, 
B12, PG16, PG9 and 2G12 were purchased from Polymun Scientific (Klosterneuburg, 
Austria). The HIV-1 specific mAbs 697, 830A, 447-52-D, 1357, 1361, 1393A, 2158, 2297 
and parvovirus B19-specific mAb 1418 were kindly provided by Dr. Miroslaw Gorny.17 The 
following reagents were obtained through the NIH AIDS Reagent Program, Division of 
AIDS, NIAID, NIH: HIV-1 specific mAbs 3869, 3074, 2191, 2219, 2442, 257-D IV, 268-D 
IV, 71-31, 240-D, 50-69, 91-5, 98-6, 246-D, 126-7 from Dr. Susan Zolla-Pazner,18-28 and 
HIV-1 specific mAbs CH01, CH02, CH03, CH04, VRC-CH31, CH38, CH57, CH58, CH59, 
CH90, HG107, HG120 from Drs. Barton F. Haynes and Hua-Xin Liao.29-32 The VZV-specific 
mAb rec-RC IgG was a generous gift from Dr. Randall Cohrs,33 and the CMV mAbs 10B7, 
8C10, 1F7, 26A1 and 13D9 were kindly provided by Dr. Ada Funaro.34  
HLA-specific human mAbs were produced by cloned B cell hybridomas derived from 
pregnancy immunized individuals.35,36 All HLA-specific mAbs were selected on basis of 
lysis of HLA-bearing target cells in complement-dependent cytotoxicity (CDC) assays and 
were of the IgG isotype. The reactivity and HLA specificity of these mAbs have been 
confirmed in SAB assays. An overview of the characteristics of the 41 HLA-specific mAbs 
tested for virus cross-reactivity can be found in table 2. HLA specific-mAbs were used as 
hybridoma supernatants in which IgG concentrations ranged from 1 to 399 μg/ml (median 20 
μg/ml). 
 
Virus-specific IgG antibody detection 
All virus-specific IgG assays were performed at the Medical Microbiology department of the 
LUMC, following protocols used for standard patient care. For determining reactivity against 
VZV and EBV, chemiluminescence immunoassays (Liaison VZV IgG and Liaison EBV 
VCA IgG, Diasorin, Saluggia, Italy) were used following the manufacturer’s instructions. 
Both assays were analyzed using a Liaison XL chemiluminescence analyzer (Diasorin). 
CMV and HIV reactivity was determined by chemiluminescent microparticle immunoassays 
(Architect CMV IgG and Architect HIV Ag/Ab Combo tests (Abbott, Hoofddorp, the 
Netherlands), following the manufacturer’s instructions. These assays were analyzed using an 
Architect immunoassay analyzer (Abbott). Finally, BK polyomavirus (BKV) reactivity was 
assessed by in-house Luminex technology as described previously.37 
 
HLA antibody detection 
Virus-specific mAbs were tested for HLA reactivity using Lifecodes single antigen class I 
and class II kits (Immucor Transplant Diagnostics, Stanford, USA). All samples were diluted 
to a median concentration of 10 µg/ml (range: 0.9-14.5 µg/ml) prior to testing. Briefly, virus-
specific mAbs were incubated with HLA class I and class II single antigen beads in filter 
plates (Millipore, Billerica, USA) for 30 min in dark at room temperature. Following a wash 
step, goat anti-human IgG antibody conjugated to phycoerythrin was added to all wells and 
incubated for 30 min. After a second wash step, samples were measured on a Luminex 
platform (LabScan 100) to obtain fluorescence intensities. Data analysis was performed using 
MATCHIT! antibody software version 1.3.1 (Immucor Transplant Diagnostics).  
 
Results 
To test whether human antibodies generated against viral antigens react against HLA 
molecules, we obtained 51 virus-specific human mAbs and tested them in SAB assays, 
covering 30 HLA-A, 48 HLA-B, 18 HLA-C, 38 HLA-DR, 31 HLA-DQ and 27 HLA-DP 
antigens. Background corrected mean fluorescence intensity (BCA) values were below zero 
for all HLA coated beads in all samples (exemplified in figure 1). 
To determine whether cross-reactivity with viral antigens could be detected for HLA-specific 
antibodies, we selected 41 HLA-specific human mAbs, covering a wide range of HLA 
epitopes recognized.36,38,39 These mAbs were tested against common viral antigens of VZV, 
EBV, CMV, HIV, and BKV in routine assays that are in place for clinical samples in our 
hospital. As can be seen in Table 3, no cross-reactivity of any of the mAbs with any of the 
viral antigens was observed. 
 
Discussion 
Evidence for the presence of antibody cross-reactivity between viral antigens and HLA 
molecules is scarce and anecdotal. Increased levels of HLA antibodies upon viral infection or 
vaccination could be either due to bystander activation of (memory) B cell clones, or due to 
true heterologous immunity.14 Thus far, no studies have been performed with the aim to 
distinguish between these two scenarios. Assaying polyclonal sera from HLA immunized 
patients is unlikely to provide a clear answer, since it is not possible to discriminate between 
true responses against viral antigens and cross-reactivity. The availability of virus-specific 
and HLA-specific human mAbs allowed us to determine whether virus-specific antibodies 
can react with HLA antigens, and vice-versa, in a controlled manner. Making use of clinically 
validated assays used for patient diagnostics allowed for reliably analyzing the reactivity to 
common HLA alleles and viral antigens. 
We analyzed the reactivity of 51 human virus-specific monoclonal antibodies against a total 
of 192 HLA alleles, resulting in 9792 possible combinations. If heterologous immunity of the 
antibody compartment would be a common feature, like heterologous T cell immunity, at 
least some, if not several positive reactions would have been expected. Concomitantly, we 
analyzed the reaction patterns of 41 human HLA-specific monoclonal antibodies with 
antigens of 5 different, some highly prevalent viruses, resulting in 205 possible combinations. 
This analysis again showed a complete lack of cross-reactivity, making the existence of 
heterologous immunity in the antibody compartment an event with very low prevalence, if 
present at all.  
The use of a total of 92 monoclonal antibodies allowed for a straightforward analysis in a 
clean testing environment. These monoclonal antibodies represent high affinity B cell clones 
producing IgG antibodies, which leaves the possibility that heterologous immunity may be 
present in low affinity B cells, which we could not address in our assays. Our previously 
performed T cell analyses on virus-specific T cells clones showed that at least for T cells, 
high affinity virus-specific clones were cross-reactive.6 While serum analysis possibly could 
be useful to address the point of low affinity B cell crossreactivity, the possible admixture of 
HLA specificities and virus specificities without knowing whether the immunizing event was 
HLA or virus, would make drawing solid conclusions very difficult.  
 
Interestingly, for many neutralizing HIV-1-specific human monoclonal antibodies it has been 
described that they are polyreactive and can bind with high avidity to mammalian 
autoantigens.40 Indeed, for at least two of the HIV-specific monoclonal antibodies described 
herein (2F5 and 4E10), human kynureninase and splicing factor 3b subunit 3 have been 
identified as the primary autoantigenic targets.41 Nonetheless, no reactivity towards HLA 
could be detected, even whit the highly sensitive SAB Luminex analysis. Additional testing 
of such polyreactive antibodies may provide useful information in the future. 
 
The apparent contradiction between absence or low frequency of antibody crossreactivity and 
the relatively high frequency of T cell crossreactivity with allogeneic HLA (45% of all T cell 
clones are crossreactive) can be explained on theoretical grounds. T cells are educated in the 
thymus to recognize self HLA with a peptide, albeit with low to intermediate affinity.14 This 
results in a relatively high chance to recognize other HLA antigens that are structurally 
highly homologous. In contrast, B cells are not selected on reactivity with self-HLA 
presenting peptide. Rather, all self-HLA reactive B cells will be eliminated in the bone 
marrow at the early developmental stage. 
 
The data presented here suggest that the presence of crossreactivity in the B cell compartment 
at levels relevant to clinical transplantation is highly unlikely. The emergence of HLA 
antibodies upon viral infection or vaccination is therefore likely due to bystander activation 
of dormant HLA-specific memory B cells. In light of the many thousands of virus-specific 
monoclonal antibodies that have been generated, this study represents a first step in 
determining whether heterologous immunity exists on the humoral level. Furthermore, assays 
to determine the presence of HLA-specific memory B cells are available,42-45 allowing to 
formally address the question whether HLA antibody formation upon viral infections or 
vaccination is due to bystander activation of dormant HLA-specific memory B cells. 
 
Acknowledgements 
The authors would like to thank Dr. Miroslaw Gorny, Dr. Randall Cohrs and Dr. Ada Funaro 
for generously providing us with the virus-specific mAbs, and Hendrik-Jan Gerritsen for 
performing the CMV, EBV, HIV and VZV serology analyses.  
Figure legends 
 
Figure 1. Virus-specific monoclonal antibodies show no cross-reactivity with HLA 
molecules. Panel A and B show representative examples of virus-specific antibody reactivity 
towards HLA in Luminex single antigen bead assays. Background corrected mean 
fluorescence intensity (BCM) values are shown, which were negative for all virus-specific 
monoclonal antibodies tested. Panel C shows the negative and positive control values for all 
Luminex single antigen bead assays performed. MFI: mean fluorescent intensity, nc: negative 
controls, pc: positive controls. 
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Tables 
Table 1. Virus-specific monoclonal antibodies tested. 
Clone Specificity Isotype Epitope 
37G12 HIV-1 p24 IgG1, κ  
2F5 HIV-1 gp41 IgG1, κ ELDKWA 
4E10 HIV-1 gp41 IgG1, κ NWFDIT 
3D6 HIV-1 gp41 IgG1, κ SGKLICTTA 
5F3 HIV-1 gp41 IgG1, λ QNQQEKNE 
4B3 HIV-1 gp41 IgG1, λ SGKLIC 
B12 HIV-1 gp120 (CD4bs) IgG1, κ discontinuous 
PG16 HIV-1 gp120 (V3/glycan) IgG1, λ discontinuous 
PG9 HIV-1 gp120 (V3/glycan) IgG1, λ discontinuous 
2G12 HIV-1 gp120 (carbo) IgG1, κ mannose? 
447-52-D HIV-1 gp120 (V3) IgG3, λ KRIHIGPGR 
697 HIV-1 gp120 (V2) IgG1, λ discontinuous 
830A HIV-1 gp120 (V2) IgG3, κ discontinuous 
1357 HIV-1 gp120 (V2) IgG1, κ discontinuous 
1361 HIV-1 gp120 (V2) IgG1, κ discontinuous 
1393A HIV-1 gp120 (V2) IgG1, κ discontinuous 
2158 HIV-1 gp120 (V2) IgG1, κ discontinuous 
2297 HIV-1 gp120 (V2) IgG1, λ discontinuous 
3869 HIV-1 gp120 (V3) IgG1, λ  
3074 HIV-1 gp120 (V3) IgG1, λ  
2191 HIV-1 gp120 (V3) IgG1, λ  
2219 HIV-1 gp120 (V3) IgG1, λ  
2442 HIV-1 gp120 (V3) IgG1, λ  
257-D IV HIV-1 gp120 (V3) IgG1, λ KRIHI 
268-D IV HIV-1 gp120 (V3) IgG1, λ HIGPGR 
71-31 HIV-1 p24 IgG1, λ  
240-D HIV-1 gp41 IgG1, κ LLGIWGCSG 
50-69 HIV-1 gp41 IgG1, κ discontinuous 
91-5 HIV-1 p24 IgG1, λ  
98-6 HIV-1 gp41 IgG1, κ SLIEESQNQQEKNEQELLEL 
246-D HIV-1 gp41 IgG1, κ QQLLGIWG 
126-7 HIV-1 gp41 IgG1, λ  
CH01 HIV-1 V1V2 IgG1  
CH02 HIV-1 V1V2 IgG1  
CH03 HIV-1 V1V2 IgG1  
CH04 HIV-1 V1V2 IgG1  
VRC-CH31 HIV-1 (CD4bs) IgG1  
CH38 HIV-1 (C1) IgG1  
CH57 HIV-1 (C1) IgG1  
CH58 HIV-1 (V2) IgG1  
CH59 HIV-1 (V2) IgG1  
CH90 HIV-1 (C1) IgG1  
HG107 HIV-1 (V2) IgG1  
HG120 HIV-1 (V2) IgG1  
1418 Parvovirus B19 VP1 IgG1, κ Not determined 
Rec-RC IgG VZV gH/gL IgG1, κ  
10B7 CMV gB IgG1  
8C10 CMV gB IgG1  
1F7 CMV gH IgG1  
26A1 CMV IgG1  
13D9 CMV IgG1  
 
 Table 2. HLA-specific monoclonal antibodies tested. 
 
Clone HLA-specificity defined by CDC Isotype 
BOY6C1 B27/B73 IgG, κ 
OK8F12 B72/B62/B46 IgG1, κ 
HDG2G7 A32/A23/A25/B49/B38/B58 IgG1, κ 
IND7D2 B21/B15/B52/B72/B56 IgG1, κ 
DK1G8 A29 IgG1, κ 
VTM1F11 B27/B7/B60 IgG1, κ 
DK7C11 B12 IgG1, κ 
VIE6C10 A23 IgG1, κ 
WK1D12 B7/B27/B60 IgG1, κ 
BVK1F9 B8 IgG1, κ 
IND3H3 A9(weak) IgG1, κ 
WIM8E5 A1/A10/A11/A9/A29/A30/A31/A33/A28 IgG1, κ 
WAR5D5 B7/B27/B42/B55 IgG1, κ 
MUL4C8 A3/A11 IgG1, κ 
SN607D8 A2/A28 IgG1, κ 
HDG11G12 B62/B5/B35/B72 /B53 IgG1, κ 
VTM4D9 B7/B27 weak IgG1, κ 
KLL5E10 B51/B52 IgG1, κ 
VTM9A10 B7/B27  IgG1, κ 
MUL9E11 B55/B57? IgG1, κ 
VIN1B10 A1/A11 (provisional) IgG1, κ 
GV2D5 A1 IgG1, κ 
BOY2A7 A10, A11 IgG1, κ 
RTLK1E2 DR3+DR5+DR6+DR8 (weak) IgG1, κ 
VR1H5 DR11 (weak) IgG1, κ 
RTLK10E12 DR11 IgG1, κ 
VTM3A1 B7 IgG1, κ 
HDG8D9 B51/B35 IgG1, λ 
BRO11F6 A11 IgG1, λ 
SN230G6 A2/B17 IgG1, λ 
GV5D1 A1/A9 (not A*2403; A80 weak) IgG1, λ 
MUS4H4 Bw4/A24/A32/A25 IgG1, λ 
OUW4F11 Bw6 IgG1, λ 
DMS4G2 B70/B39/B50/B62/B45/B60/B61/B41 (provisional) IgG1, λ 
HDG4B1 B57/B63/A32/A25 IgG1, λ 
MUL2C6 A3/A11/A24 IgG1, λ 
KAL3D5 B51/B52/B77 IgG1, λ 
SN7B12 B17 IgG1, λ 
TL3B6 DPBB1*0101+0301+0901DP epitope 85 DEAV  IgG1, λ 
ZEL4F11 B60/B61/B7/B55/B56/B18/B13/B8/B62/B35/B38/ B78/B81 IgG3, κ 
ROU9A6 B12/B13/B40/B21/B41 IgG3, λ 
Table 3. Results of HLA-specific monoclonal antibodies tested against common viral antigens of VZV, EBV, CMV, HIV, and BKV in routine 
clinical assays. 
 
Clone 
VZV IgG 
(mIU/ml. interpretation) 
EBV VCA 
(IgG U/ml, interpretation) 
CMV IgG  
(AU/ml, interpretation) 
HIV IgG 
(S/CO, interpretation) 
BKV  
(IgG MFI, interpretation)  
BOY6C1 <10,0 Negative <10,0 Negative 0,0 Negative 0,13 Negative 69,5 Negative 
OK8F12 <10,0 Negative <10,0 Negative 0,0 Negative 0,11 Negative 65,5 Negative 
HDG2G7 <10,0 Negative <10,0 Negative 0,0 Negative 0,09 Negative 59,5 Negative 
IND7D2 <10,0 Negative <10,0 Negative 0,0 Negative 0,11 Negative 57,5 Negative 
DK 1G8 <10,0 Negative <10,0 Negative 0,0 Negative 0,15 Negative 60 Negative 
VTM1F11 <10,0 Negative <10,0 Negative 0,0 Negative 0,14 Negative 58,5 Negative 
DK7C11 <10,0 Negative <10,0 Negative 0,0 Negative 0,15 Negative 65 Negative 
VIE6C10 <10,0 Negative <10,0 Negative 0,0 Negative 0,12 Negative 61,5 Negative 
WK1D12 <10,0 Negative <10,0 Negative 0,0 Negative 0,24 Negative 61 Negative 
BVK1F9 <10,0 Negative <10,0 Negative 0,0 Negative 0,17 Negative 63,5 Negative 
IND3H3 <10,0 Negative <10,0 Negative 0,0 Negative 0,12 Negative 59,5 Negative 
WIM8E5 <10,0 Negative <10,0 Negative 0,0 Negative 0,13 Negative 59 Negative 
WAR5D5 <10,0 Negative <10,0 Negative 0,0 Negative 0,10 Negative 61 Negative 
MUL4C8 <10,0 Negative <10,0 Negative 0,0 Negative 0,11 Negative 56 Negative 
SN607D8 <10,0 Negative <10,0 Negative 0,0 Negative 0,18 Negative 59 Negative 
HDG11G12 <10,0 Negative <10,0 Negative 0,0 Negative 0,11 Negative 65 Negative 
VTM4D9 <10,0 Negative <10,0 Negative 0,0 Negative 0,13 Negative 63,5 Negative 
KLL5E10 <10,0 Negative <10,0 Negative 0,0 Negative 0,09 Negative 52 Negative 
VTM9A10 <10,0 Negative <10,0 Negative 0,0 Negative 0,08 Negative 57 Negative 
MUL9E11 <10,0 Negative <10,0 Negative 0,0 Negative 0,13 Negative 53,5 Negative 
VIN1B10 <10,0 Negative <10,0 Negative 0,0 Negative 0,12 Negative 56 Negative 
GV2D5 <10,0 Negative <10,0 Negative 0,0 Negative 0,11 Negative 56 Negative 
BOY2A7 <10,0 Negative <10,0 Negative 0,0 Negative 0,12 Negative 59 Negative 
RTLK1E2 <10,0 Negative <10,0 Negative 0,0 Negative 0,09 Negative 51 Negative 
VR1H5 <10,0 Negative <10,0 Negative 0,0 Negative 0,08 Negative 64 Negative 
RTLK10E12 <10,0 Negative <10,0 Negative 0,0 Negative 0,06 Negative 61 Negative 
VTM3A1 <10,0 Negative <10,0 Negative 0,0 Negative 0,09 Negative 63 Negative 
HDG8D9 <10,0 Negative <10,0 Negative 0,0 Negative 0,14 Negative 61,5 Negative 
BRO11F6 <10,0 Negative <10,0 Negative 0,0 Negative 0,10 Negative 61 Negative 
SN230G6 <10,0 Negative <10,0 Negative 0,0 Negative 0,12 Negative 79 Negative 
GV5D1 <10,0 Negative <10,0 Negative 0,0 Negative 0,14 Negative 60 Negative 
MUS4H4 <10,0 Negative <10,0 Negative 0,0 Negative 0,07 Negative 61,5 Negative 
OUW4F11 <10,0 Negative <10,0 Negative 0,0 Negative 0,20 Negative 54 Negative 
DMS4G2 <10,0 Negative <10,0 Negative 0,0 Negative 0,11 Negative 50,5 Negative 
HDG4B1 <10,0 Negative <10,0 Negative 0,0 Negative 0,10 Negative 49 Negative 
MUL2C6 <10,0 Negative <10,0 Negative 0,0 Negative 0,09 Negative 50,5 Negative 
KAL3D5 <10,0 Negative <10,0 Negative 0,0 Negative 0,07 Negative 60,5 Negative 
SN7B12 <10,0 Negative <10,0 Negative 0,0 Negative 0,09 Negative 61,5 Negative 
TL3B6 <10,0 Negative <10,0 Negative 0,0 Negative 0,07 Negative 58 Negative 
ZEL4F11 <10,0 Negative <10,0 Negative 0,0 Negative 0,11 Negative 54 Negative 
ROU9A6 <10,0 Negative <10,0 Negative 0,0 Negative 0,12 Negative 52 Negative 
VZV: varicella zoster virus 
EBV: Epstein-Barr virus 
CMV: cytomegalovirus 
HIV: human immunodeficiency virus 
BKV: BK polyomavirus 
MFI: mean fluorescence intensity 
Cut-off MFI value for BKV: 478 
 
 
